Neumora Therapeutics (NMRA) Non Operating Income (2022 - 2026)
Neumora Therapeutics' quarterly Non Operating Income came in at -$564000.0 in Q1 2026, down 2156.0% year-on-year from $27431.9 in Q1 2025, and up 90.75% quarter-over-quarter from -$6.1 million in Q4 2025.
Neumora Therapeutics has reported Non Operating Income for 5 years, with the latest figure at -$564000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 2156.0% year-over-year to -$564000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.3 million (down 156.64% YoY), and the FY2025 full-year result was -$767000.0, down 883.33% from the prior year.
- Non Operating Income for Q1 2026 stood at -$564000.0, up from -$6.1 million in the prior quarter.
- The five-year high for Non Operating Income was $6.4 million in Q1 2024, with the low at -$6.1 million in Q4 2025.
- Average Non Operating Income over 5 years is $1.3 million, with a median of $15000.0 recorded in 2024.
- Year-over-year, Non Operating Income soared 24534.62% in 2024 and plunged 40733.33% in 2025.
- Tracing NMRA's Non Operating Income over 5 years: stood at -$2.0 million in 2022, then soared by 378.63% to $5.5 million in 2023, then plunged by 99.73% to $15000.0 in 2024, then sank by 40733.33% to -$6.1 million in 2025, then surged by 90.75% to -$564000.0 in 2026.
- The last three Non Operating Income figures came in at -$564000.0 (Q1 2026), -$6.1 million (Q4 2025), and $7000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -564,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -564,000.00 |
| Dec 31, 2025 | -6.10 Mn |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 6.35 Mn |
| Dec 31, 2023 | 5.54 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | -39,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -1.99 Mn |
| Sep 30, 2022 | 1.26 Mn |